-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Cytokinetics, Raises Price Target to $84

Benzinga·12/22/2025 11:43:24
Listen to the news
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $72 to $84.